Antiplatelet therapy and outcomes: logistic regression analyses
| Predictor | OR | 95% CI | p Value |
|---|---|---|---|
| Total mortality | |||
| Antiplatelet therapy | 0.63 | 0.47 to 0.85 | 0.003 |
| Age | 1.02 | 1.00 to 1.03 | 0.032 |
| Neoplastic disease | 2.44 | 1.63 to 3.67 | <0.0001 |
| MRC dyspnoea score | 1.83 | 1.56 to 2.16 | <0.0001 |
| Long term oxygen therapy | 1.70 | 1.10 to 2.62 | 0.016 |
| Residence in long term care facility | 2.54 | 1.42 to 4.54 | 0.002 |
| Acidosis | 1.93 | 1.36 to 2.74 | 0.0002 |
| Hosner–Lemeshow goodness of fit test p=0.687 | |||
| Inhospital mortality | |||
| Antiplatelet therapy | 0.69 | 0.41 to 1.11 | 0.124 |
| Age | 1.03 | 1.00 to 1.05 | 0.046 |
| Neoplastic disease | 1.91 | 1.06 to 3.45 | 0.030 |
| Acidosis | 5.19 | 3.14 to 8.58 | <0.0001 |
| BAP-65 | 1.82 | 1.37 to 2.42 | <0.0001 |
| Hosner–Lemeshow goodness of fit test p=0.957 | |||
| Mortality after discharge | |||
| Antiplatelet therapy | 0.62 | 0.46 to 0.85 | 0.003 |
| Age | 1.02 | 1.01 to 1.03 | 0.014 |
| Neoplastic disease | 2.30 | 1.47 to 3.59 | 0.0003 |
| MRC dyspnoea score | 1.99 | 1.66 to 2.38 | <0.0001 |
| Long term oxygen therapy | 1.73 | 1.08 to 2.76 | 0.022 |
| Residence in long term care facility | 2.16 | 1.14 to 4.09 | 0.018 |
| Hosner–Lemeshow goodness of fit test p=0.600 | |||
MRC, Medical Research Council.